

# 1. CURRICULUM VITAE

## 1.1. GENERAL INFORMATION

Name, Surname: Krackhardt, Angela Madeleine  
Academic degree: Univ.-Prof. Dr. med.  
Birth date: July 17<sup>th</sup>, 1970  
Nationality German  
Marital status Married  
Confession Evangelisch-Lutherisch  
Language skills German, English, French  
Address Malteser Norddeutschland gGmbH  
Malteser Krankenhaus St. Franziskus-Hospital  
First Medical Department  
Waldstr. 17  
24939 Flensburg  
Tel. + 49 (0) 461 816 2512  
Fax. +49 0) 461 816 2022  
Email: angela.krackhardt@malteser.org

## 1.2. CURRENT POSITIONS

- Chief Physician and Head of the First Medical Department, Malteser Krankenhaus St. Franziskus-Hospital, Malteser Norddeutschland gGmbH
- W2 Full Professorship Translational Immunotherapy (on sabbatical), IIIrd Medical Department, TUM School of Medicine, TU München, Munich, Germany
- Researcher at Translatum, TUM School of Medicine, TU München, Munich, Germany

## 1.3. EDUCATION UND STUDY

1976-1980 Grundschule (Wiestorschule Überlingen)  
1980-1989 Gymnasium (Gymnasium Überlingen)  
1989-1991 Preclinical medical studies, Freie Universität Berlin, Germany  
1991 Physikum  
1991-1996 Clinical medical studies; Freie Universität Berlin, Germany  
1992 German 1. Staatsexamen; Freie Universität Berlin, Germany  
1993-1994 Clinical medical studies; Hôpital Pitié-Salpêtrière, Paris, France  
1994-1995 Clinical medical studies; Freie Universität Berlin, Germany  
1995 German 2. Staatsexamen; Freie Universität Berlin, Germany  
1995-1996 German Practical Year in Medicine in Berlin, Germany, and Pittsburg, USA  
1996 German 3. Staatsexamen; Freie Universität Berlin, Germany

## 1.4. SCIENTIFIC CAREER

1993-1998 MD thesis, Supervisor: Prof. Dr. E. Thiel

1998	Graduation as Dr. med. Title: In vitro elimination of malignant cells in patients with chronic myeloid leukemia by activation of autologous lymphocytes with combination of cytokines and anti-CD3 monoclonal antibodies – analysis of efficacy by flow cytometry and PCR; Freie Universität Berlin, Magna cum laude
1996 – 1999	Research Associate in Hematology, Oncology and Transfusion Medicine, Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany, Director: Prof. Dr. med. E. Thiel
1999 – 2001	Research Associate, Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Research group leader: J. Gribben, D.Sc., F.R.C.P., F.R.C.Path., F.Med.Sci.
2001 – 2002	Instructor in Medicine, Faculty, Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2002 – 2004	Research Associate in Hematology, Oncology and Transfusion Medicine, Medizinische Klinik III, Charité, Campus Benjamin Franklin, Berlin, Germany; Director: Prof. Dr. E. Thiel
2005 – 2010	Junior Research Group Leader (Adoptive T cell therapy), Institute of Molecular Immunology; Helmholtz Zentrum München (HMGU), National Research Institute for Environment and Health, München, Germany; Chair: Prof. Dr. D. Schendel
Since 2010	Research Group Leader, Medizinische Klinik III, MRI/TUM, München, Germany; Chair: Prof. Dr. C. Peschel, now Prof. Dr. F. Bassermann
2010	Habilitation treatise, Title: Antigen-spezifische zelluläre Immuntherapien – Perspektiven – Herausforderungen – Strategien (Antigen-specific cellular immunotherapies – perspectives – challenges – strategies)
2010-2014	W2-Professorship of Translational Immunotherapy, Medizinische Klinik III, MRI/TUM, München, Germany; Director: Prof. Dr. C. Peschel
Since 2014	W2-Professorship (tenured) for Translational Immunotherapy, Medizinische Klinik III, MRI/TUM, München, Germany; Director: Prof. Dr. C. Peschel, now Prof. Dr. F. Bassermann
Since 2019	Research group leader at the Translatum, TUM

Scientific focus: Cancer Immunotherapy, Antigen identification, Neoantigens, T-cell receptor characterization, Immunoimaging, Immunomodulation, Clinical Translation

## 1.5. CLINICAL CAREER

1996	Limited approbation as a medical doctor (Ärztin im Praktikum)
1996-1998	Junior Resident Fellow (Ärztin Im Praktikum) in Hematology, Oncology and Transfusion Medicine, Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany, Chair: Prof. Dr. med. E. Thiel
1996-1998	Hemato-oncological ward
1998	Full approbation as a medical doctor
1998-1999	Resident Fellow in Hematology, Oncology and Transfusion Medicine, Medizinische Klinik III, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany, Chair: Prof. Dr. E. Thiel
1998-1999	Emergency room and admission ward
2002 – 2004	Resident Fellow in Hematology, Oncology and Transfusion Medicine, Medizinische Klinik III, Charité, Campus Benjamin Franklin, Berlin, Germany; Director: Prof. Dr. E. Thiel
2002	Intensive Care Unit
2003-2004	Hemato-oncological ward and CLL clinic
2010-2012	Clinical Associate, Medizinische Klinik III, MRI/TUM, München, Germany; Chair Prof. Dr. C. Peschel
2010-2011	Allogeneic Stem Cell Transplantation Unit
Since 2011	Outpatient Clinics (Tumor-Therapie-Zentrum -TTZ)

2011	Authentication as specialist for Internal Medicine (Fachärztin für Innere Medizin, Bayerische Landesärztekammer, Weiterbildungsordnung von 1993)
2012	Senior physician of the interdisciplinary melanoma clinic and board
2013	Authentication of the accessory designation as specialist for Hematology and Clinical Oncology (Erwerb der Zusatzbezeichnung Hämatologie und Internistische Onkologie, Bayerische Landesärztekammer, Weiterbildungsordnung von 1993)
2018-2023	Senior physician and attending, Klinik und Poliklinik für Innere Medizin III, MRI/TUM, München, Germany; Chair: Prof. Dr. F. Bassermann
2018-2019	Head of the Outpatient Clinic, Klinik und Poliklinik für Innere Medizin III, MRI/TUM, München, Germany; Chair: Prof. Dr. F. Bassermann
2018-2023	Leading attending for the Specific Cellular Immunotherapy Program, Klinik und Poliklinik für Innere Medizin III, MRI/TUM, München, Germany; Chair: Prof. Dr. F. Bassermann
2023	Chief Physician and Head of the First Medical Department, Malteser Krankenhaus, St. Franziskus-Hospital, Flensburg

Clinical focus: Immunotherapy, immune checkpoint inhibitors, specific cellular therapy, skin tumors, multiple myeloma

## 1.6. CLINICAL RESEARCH

Since 2010	Investigator and Sub-Investigator in multiple Phase I-III clinical trials
2014	Initiation of an own Investigator-Initiated Trial (Her2 peptide vaccination)

## 1.7. GMP AND QUALITY MANAGEMENT

2010-2021	Member of the GMP facility of the apheresis unit for collection and cryopreservation of hematopoietic stem cells, Medizinische Klinik III, MRI/TUM, Munich, Germany; Chair: Prof. Dr. C. Peschel
2012-2021	Head of the GMP facility and apheresis unit for collection and cryopreservation of autologous and allogeneic hematopoietic stem cells and lymphocytes, Klinik und Poliklinik für Innere Medizin III, MRI/TUM, München, Germany; Chair: Prof. Dr. C. Peschel, since 2017 Prof. Dr. F. Bassermann
2012-2021	Appointment as qualified person by the Regierung von Oberbayern (German AMG, §13) Klinik und Poliklinik für Innere Medizin III, MRI/TUM, München, Germany; Chair: Prof. Dr. C. Peschel, since 2017 Prof. Dr. F. Bassermann
2020-2021	Qualified person TUMCells for cryopreservation of autologous and allogeneic hematopoietic stem cells and lymphocytes

## 1.8. PRIZES AND AWARDS

1994	Berliner Krebsgesellschaft, Travel Award (DGHO Jahrestagung, Wien, Österreich)
1998	Deutsche Krebshilfe Travel Award (Dendritic Cell Symposium, Pittsburgh, PA, USA)
1999	Deutsche Krebshilfe Research Award
2000	American Society of Hematology Travel Award (ASH Meeting, San Francisco, CA, USA)
2005	Life Science Foundation Research Award
2008	BayImmuneNet Research Award
2010	Förderung Sonderprogramm Neuberufene Professorinnen (Universität Bayern e.V.)

## 1.9. HONORARY AND MEMBERSHIPS

2012	Appointment to the Advisory Board of the IZKF Würzburg, University Würzburg
2012	Appointment to the Faculty Board for the Graduate Program Translational Medicine, TUM
2015	Speaker of the Munich section Cancer Immunotherapy within the DKTK

- 2019 Appointment to the Faculty Board of the PhD Graduate Program, Faculty of Medicine, TUM  
2021 Appointment to the scientific advisory group (SAG) at the European Medicines Agency (EMA)

## 1.10. SOCIETY AND MEMBERSHIPS

Deutsche Gesellschaft für Immunologie (DGfI)  
Bund Deutscher Internisten (BDI)  
Association for Cancer Immunotherapy (CIMT)  
German lymphoma alliance (GLA)  
Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)  
Society of Immunotherapy of Cancer (SITC)  
Deutsche Krebsgesellschaft (DKG)

## 1.11. REVIEWER ACTIVITY AND ADVISORY BOARDS

Research Foundations (selected):

European Research Council (ERC), Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe, Deutscher Akademischer Austauschdienst (DAAD), Gene Therapy Advisory Committee (GTAC)/UK, Genome Canada, Denmark Technical University, 2019 Appointment to the Advisory Board of the EU Consortium Immune Image, U.S.-Israel Binational Science Foundation

Research Journals (selected):

Science Immunology, Nature Biomedical Engineering, Nature Communications, Blood, Clinical Cancer Research, Journal of Nuclear Medicine, Journal of Translational Medicine, Journal of Immunology, Journal of Immunological Methods, Journal of Cancer research and Clinical Oncology, Carcinogenesis, Frontiers in Immunology, Cancer Immunology Immunotherapy, Theranostics

Industrial Advisory Activity:

Secarna, Vaccibody, Zelluna, Kiadis, BMS, Novartis, Takeda, Roche, Sanofi, Pierre-Fabre, Janssen, Gilead